Seeking Alpha

Gilead Sciences (GILD +4.7%) is one of the best performers in the S&P 500 today after...

Gilead Sciences (GILD +4.7%) is one of the best performers in the S&P 500 today after JPMorgan analyst Geoff Meacham came out with some positive comments about the company's new HIV medication Stribild and hepatitis C drug program, and raised his price target to $75 from $70.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|